Wells Fargo says that commentary on Tenet Healthcare’s (THC) earnings call was generally as it would have been expected. Tenet is not yet ready to discuss 2026, including potential impact from enhanced subsidy expiration or jump-off considerations, Wells adds. The firm has an Overweight rating on the shares with a price target of $195.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THC:
- Morning Movers: Lockheed Martin slips following second quarter report
- Tenet Healthcare reports Q2 adjusted EPS $4.02 ,consensus $2.87
- Tenet Healthcare sees 2025 EPS $15.55-$16.21, consensus $12.84
- Notable companies reporting before tomorrow’s open
- TD says CMS hospital rules positive for Surgery Partners, negative for HCA